Midostaurin__Kinase inhibitor JNJ-40411814
Product Name
Midostaurin
Description
Kinase inhibitor
Purity
>98% (TLC)
CAS No.
120685-11-2
Molecular Formula
C35H30N4O4
Molecular Weight
570.6
Storage Temperature
-20ºC
Shipping Temperature
Shipped Ambient
Product Type
Inhibitor
Solubility
Soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml) or 100% ethanol (2.5 mg/ml)
Source
Synthetic
Appearance
White to off-white powder
SMILES
N48C1=C(C7=C(C2=C1N(C3=CC=CC=C23)C@@H5OC@4(C@@(C@@H5N(C)C(=O)C6=CC=CC=C6)(OC)C)C)C(NC7)=O)C9=C8C=CC=C9
InChI
InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(
InChIKey
BMGQWWVMWDBQGC-PZFYLCKJSA-N
Safety Phrases
Classification:
Not a hazardous substance or mixture.
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
Cite This Product
Midostaurin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-468)
Alternative Names
4’-N-Benzoyl-staurosporine, PKC-412, CGP 41251
Research Areas
Cancer, Apoptosis, Cancer Growth Inhibitors, Cell Signaling, Tyrosine Kinase Inhibitors
PubChem ID
24202429
Scientific Background
Midostaurin is a broad spectrum protein kinase inhibitor. It also shows inhibition of PKCα, PKCβ and PKCγ isoforms, Flk, and c-kit. Midostaurin displays antiproliferative characteristics and the ability to induce apoptosis.
References
1. Fabbro D., et al. (2000) Anti-Cancer Drug Design. 15(1): 17–28.
2. Odgerel, T., et al. (2008) Oncogene. 27(22): 3102–3110.
3. Bahlis, N.J., et al. (2005) Leukemia & Lymphoma. 46(6): 899–908.
Kinase inhibitor
Not a hazardous substance or mixture.
Safety Phrases:
S22 – Do not breathe dust.
S24/25 – Avoid contact with skin and eyes.
S36/37/39 – Wear suitable protective clothing, gloves and eye/face protection.
2. Odgerel, T., et al. (2008) Oncogene. 27(22): 3102–3110.
3. Bahlis, N.J., et al. (2005) Leukemia & Lymphoma. 46(6): 899–908.